Zydus Settles On Revlimid In US
Agreement Brings To An End Indian Firm's Lenalidomide Litigation
Zydus Cadila has settled US patent litigation with Celgene over its proposed lenalidomide generic, marking the latest in a line of settlements over the Revlimid brand.
You may also be interested in...
Cipla has become the latest generics firm to settle US patent litigation with Bristol Myers Squibb’s Celgene over its Revlimid blockbuster.
Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.
Alvogen can sell in the US generic lenalidomide on a volume-limited basis after March 2022, and without volume limitations in early 2026, after settling patent litigation with Celgene relating to the originator’s Revlimid. Dr Reddy's has also settled in Canada.